Monitor Phase 1 SL-325 data release in Q2 2026; positive data could catalyze significant upside. No near-term revenue catalysts.
Price Chart
Executive Summary
Shattuck Labs reported Q1 2026 net loss of $0.13 per share, slightly better than consensus of -$0.14, but the company remains pre-revenue with no product sales. The key update is completion of Phase 1 enrollment for SL-325, with data expected in Q2 2026. Cash position strengthened to $90.4M, extending runway into 2029.
Key Financial Metrics
Key Facts
- Phase 1 trial of SL-325 enrollment complete; data expected Q2 2026
- Cash and investments $90.4M as of March 31, 2026, up from $54.2M at Dec 31, 2025
- Net loss $14.8M ($0.13/share) vs $13.7M ($0.27/share) in Q1 2025
- No revenue reported in Q1 2026 or Q1 2025
- Cash runway expected to fund operations into 2029 assuming warrant exercise
Financial Impact
Net loss per share -$0.13 vs consensus -$0.14 (7.1% beat), but pre-revenue, cash burn increases slightly
Risk Factors
- Phase 1 data may disappoint, delaying Phase 2 initiation
- Cash burn may increase with Phase 2 costs, potentially requiring additional financing
- No approved products; dependent on clinical trial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031643 |
| Document: sttk-20260507.htm | 0001628280-26-031643 |
| Document: 0001628280-26-031643-index-headers.html | 0001628280-26-031643 |
| Document: 0001628280-26-031643-index.html | 0001628280-26-031643 |
| Document: 0001628280-26-031643.txt | 0001628280-26-031643 |
| 8-K Data (Synthetic) | 0001628280-26-031643 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 11w ago | 8-K | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Aug 11, 2026 11w ago | Press Release | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Jul 7, 2026 15w ago | Insider Cluster | $6.88 $6.29 | ▼ −8.58% | ▼ −9.44% | $5.54 (−19.48%) |
Jul 2, 2026 16w ago | Insider Cluster | $7.05 $7.03 | ▼ −0.28% | ▼ −1.21% | $5.54 (−21.42%) |
Jun 11, 2026 19w ago | 8-K | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | 424B5 | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 10, 2026 19w ago | Press Release | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 424B5 | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 8-K | $4.13 $4.33 | ▲ +4.84% | ▲ +1.41% | $5.54 (+34.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers